Introduction/Background Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) is a rare malignancy with a grave prognosis. Available information on SCCOHT among Indian women is limited. This study aimed to describe the clinical characteristics, treatment, and outcomes in SCCOHT patients.

Methodology We conducted a retrospective review of 8 patients with SCCOHT treated at Tata Medical Center between 2012 and 2021. Relevant data were obtained from electronic medical records. Standard descriptive and survival statistics were used in the analysis.

Results The median age at diagnosis was 41.5 years (range, 21–60). Abdominal pain (100%), and abdominal distension (62.5%) were the two most common presenting symptoms. Six (75%) patients had stage IVB at initial diagnosis, 1 had stage IIIC, and 1 had stage IC2. Liver was the most common site of de novo (5 of the 6 patients, 83.3%) or recurrent metastatic (2 of 2 patients, 100%) disease. All patients had an elevated CA125 with a median of 189 U/mL (40–532). Hypercalcemia (>10.2 mg/dL) was present in 3 patients (37.5%). Two patients underwent surgery - one had a fertility-sparing surgery (FSS), and the other had cytoreductive surgery following neoadjuvant chemotherapy. The patient with stage IC2 after FSS received adjuvant chemotherapy with etoposide-cisplatin (EP). Among 6 patients with initial metastatic disease, 1 died within a week, and 5 received EP chemotherapy. Two patients (40%) had an objective response. None of the patients received intensive multiagent chemotherapy. Both the patients with non-metastatic disease had recurrences within 1 year. At a median follow-up of 17.3 months, the median overall survival was 8.2 months (95% CI, 0.0–17.2).

Conclusion In this series of SCCOHT patients, most patients presented with distant metastases and had dismal overall survival.

Disclosures None